An interventional study of Ultrasound and Standard care in Postpartum Period, sponsored by Holy Family Hospital, Nazareth, Israel. Recruiting at 1 site in Israel. Open to female participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-16.
Sponsored by Holy Family Hospital, Nazareth, Israel · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Postpartum Hemorrhage with a site in Israel — 6 open to participants now, 6 under way, 1 of them phase 3. Postpartum Hemorrhage · Israel.
Among the 12 studies in Postpartum Hemorrhage with a site in Israel, this one is the 2nd largest by planned enrollment, is the only one that started in 2025, is one of 6 with no phase, and was the 9th registered.
470 studies on the registry are indexed under Postpartum Hemorrhage; 76 are open to participants now.
Browse Postpartum Hemorrhage studies →6 of the 12 studies in Postpartum Hemorrhage with a site in Israel are open now. Recruiting first, the newest first:
Holy Family Hospital, Nazareth, Israel · Sites in Israel
Ages 18–45 · Women only · Healthy volunteers
Wolfson Medical Center · Sites in Israel
Ages 18–51 · Women only · Healthy volunteers
Rambam Health Care Campus · Sites in Israel
Ages 18+ · Men only · Healthy volunteers
Sheba Medical Center · Sites in Israel
Ages 18+ · Women only
ResQ Medical Ltd · Sites in Israel, United States
Ages 18+ · Women only
A study can be open while its sites in Israel have not opened yet or have stopped. Only those recruiting at a site in Israel →
Of the 41 Postpartum Hemorrhage studies recruiting now, 21 (51%) set no upper age limit and 20 (49%) stop at 75 or younger; 6 take children under 18; 20 take healthy volunteers.
This study: 18 Years to 50 Years · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 1 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 276 is above the median of 146 across 361 interventional studies indexed under Postpartum Hemorrhage.
Median enrollment 116 across the 12 interventional studies. Of the 4 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 12 has an industry lead sponsor. The 10 most frequent:
Holy Family Hospital, Nazareth, Israel is the lead sponsor of 10 studies on the registry; 9 are open to participants now.
Holy Family Hospital, Nazareth, Israel has 2 studies filed under Postpartum Hemorrhage — fewer than ten, so there is no comparison to draw.
4 of the studies in Postpartum Hemorrhage with a site in Israel that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06646653Phase 3ResQ Medical LtdEVE TRIAL , ALMA SYSTAM | 2027-01 |
| NCT06963047Holy Family Hospital, Nazareth, IsraelEvaluation of Blood Loss After Cesarean Delivery Via US Compared to Standard Care | 2027-05-01 |
| NCT03626844Holy Family Hospital, Nazareth, IsraelMaternal Outcomes Following Manual Lysis of the Placenta. | 2027-07 |
| NCT07714902Rambam Health Care CampusAdministration Of Calcium Gluconate for The Reduction of Blood Loss During Vaginal Delivery | 2027-10-01 |
Add all 4 to your calendar (.ics) → With an account.
Among the 12 studies in Postpartum Hemorrhage with a site in Israel, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Postpartum hemorrhage and anemia are considered a major health concern due to their impact on maternal morbidity and mortality, quality of life, and maternal cognitive and emotional functioning after delivery, which are particularly important during the critical period of mother-child bonding. Hemoglobin levels in the first 24 hours after delivery do not reflect the lowest point (nadir). The postpartum nadir occurs 48-72 hours after delivery due to the initial redistribution of plasma volume. The aim of this study was to examine whether postpartum ultrasound examination precedes laboratory test results in the diagnosis of anemia due to blood loss after cesarean section.
According to the World Health Organization, postpartum anemia should be recognized as a major health concern, as it affects the quality of life, cognitive and emotional function of the mother, which are particularly important during the critical period of mother-child bonding. Additionally, anemia may impact mother-infant interaction, potentially leading to cognitive delays in infants. Furthermore, postpartum anemia increases the risk of postpartum depression, the need for blood transfusions, length of hospital stays, and hospitalization costs.
Hemoglobin (HB) levels within the first 24 hours postpartum do not reflect the lowest point (nadir). The postpartum nadir occurs 48-72 hours after birth due to initial plasma volume redistribution. Diagnosis is made by measuring HB levels, and anemia is defined when HB is below 10 g at 48 hours postpartum. Postpartum anemia requires immediate treatment upon diagnosis and preferably before discharge.
The incidence of postpartum anemia in developing countries is 50-80%. This high incidence reflects a combination of reasons including under or late diagnosis, lack of awareness, and early hospital discharge.
Postpartum hemorrhage, particularly after cesarean section (CS), is a leading cause of postpartum anemia (HB \<10 g%) as well as significant morbidity and mortality. When bleeding occurs into the abdominal cavity, diagnosis is more difficult and delayed, often only detected when vital signs become unstable. Early diagnosis is crucial for proper management of blood loss and life-saving interventions. Diagnosis includes laboratory tests and imaging modalities, and treatment is determined based on severity, ranging from iron supplementation, blood transfusions, and even surgical interventions if necessary.
A certain amount of intra-abdominal fluid is common after most CS. However, there is no standardized reference in gynecological literature regarding what fluid volume is considered normal or pathological after surgery, nor its association with complications such as pain, infection, or prolonged hospitalization. Studies have shown that free intra-abdominal fluid was detected in 73% of patients after CS using CT scans, whereas ultrasound (US) detected fluid in less than 5% of women.
Recently, advanced US technology has become available, including 3D imaging and Doppler technology, which allows for quantitative fluid volume assessment. US is considered a valuable tool for rapid assessment of intra-abdominal free fluid. It is a safe, fast, and non-invasive diagnostic modality that can be used in post-cesarean women to detect and measure intra-abdominal and pelvic fluid, causing minimal patient discomfort. US has several advantages over CT scans and most gynecology departments are equipped with US machines, and gynecologists are trained to use them in clinical practice.
Currently, there is no routine use of US to assess intra-abdominal fluid volume after CS. HB levels are only measured 24 hours post-surgery, which does not necessarily reflect the nadir value. After discharge, many postpartum women may not take iron supplements due to unrecognized anemia, poor tolerance, or low adherence. The aim of this study was to examine whether postpartum ultrasound examination compared to standard care, precedes laboratory test results in the diagnosis of anemia due to blood loss after CS.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Group 1: patients will undergo an abdominal and transvaginal ultrasound examination within 24 - 48 hours post-surgery.
Diagnostic Test: Ultrasound
Group 2: Candidates will be managed according to the standard care, i.e., without a routine postpartum ultrasound.
Other: Standard care
The purpose of the test is to diagnose and assess the amount of blood loss.
Routine management
Hemoglobin drop of 2g% or more within 24 - 36 hours
The proportion of women with a decrease in Hb levels of over 2 g% identified within 24 hours of surgery in both groups.
Time frame: 24 -72 hours
HB levels after 48-72
Difference in average HB levels after 48-72 hours between the two study groups
Time frame: 72 hours postpartum
Inferior Vena Cava (IVC) diameter
Measurement of IVC diameter during inspiration and expiration
Time frame: up to 72 hours postpartum
IVC collapsibility index
IVC expiration-IVC inspiration/IVC expiration
Time frame: up to 72 hours postpartum
Uterine walls diameter
Measured midway between the fundus and the cervix of the uterus
Time frame: up to 72 hours postpartum
Uterine endometrial diameter
Measuring the thickness of the inner layer of the uterus
Time frame: up to 72 hours postpartum
Uterine length
Measured from the external cervical os to the fundus
Time frame: up to 72 hours postpartum
Maximum vertical depth of intra-abdominal fluid
The measurement will be performed using abdominal and/or vaginal transducer
Time frame: up to 72 hours postpartum
Urine volume in the bladder
The measurement will be performed using an abdominal or vaginal transducer
Time frame: up to 72 hours postpartum
Rate of women in the study group with intra-abdominal fluid
The measurement will be performed using abdominal and/or vaginal transducer
Time frame: up to 72 hours postpartum
Intra-abdominal fluid volume
The assessment will be performed using abdominal and/or vaginal transducer
Time frame: up to 72 hours postpartum
Presence of intra-abdominal hematomas
The assessment will be performed using abdominal and/or vaginal transducer
Time frame: up to 72 hours postpartum
Objective assessment of intraoperative blood loss
Calculated blood loss = total blood volume × (prepartum hematocrit - postpartum hematocrit) + total blood volume transfused (if applicable).
Time frame: up to 72 hours postpartum
Administration of blood products
Number of blood units administrated
Time frame: up to 72 hours postpartum
Postoperative fever
Maternal fever 38C or more
Time frame: up to 72 hours postpartum
Incidence of women with surgical site infection
An infection in the part of the body where a surgery took place
Time frame: Postoperative day 2 to day 7.
Length of hospital stay
Number of days from delivery to discharge
Time frame: up to 10 days postpartum
Maternal discomfort during the ultrasound examination
Measured on a scale of 1 to 5 (1 = no discomfort, 5 = very uncomfortable).
Time frame: up to 72 hours postpartum
HB levels after 4 - 6 weeks
Difference in average HB levels 4 - 6 weeks between the two study groups
Time frame: 6 weeks postpartum
Started May 2025 (actual). Primary completion is estimated for May 2027, 23 months after the start.
Of 112 non-industry interventional studies with no phase under Postpartum Hemorrhage, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 28. This study's planned 23 months is above that.
Counting every sponsor, half of 119 studies reached it within 16 months; a quarter within 7 and three quarters within 26.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Holy Family Hospital, Nazareth, Israel